rs4783961 — CETP

CETP rs4783961 — The Promoter Variant That Reshapes Your HDL Balance

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that shuttles cholesteryl esters from HDL particles to LDL and VLDL particles in exchange for triglycerides. It is one of the central regulators of HDL cholesterol concentration in the bloodstream. Less CETP activity means fewer cholesteryl esters leave HDL — so HDL particles stay cholesterol-rich and HDL-C rises on a standard lipid test.

The rs4783961 variant sits approximately 971 base pairs upstream of the CETP transcription start site — in a regulatory region that influences how much CETP the liver produces. Unlike coding variants that change the CETP protein's structure, this promoter polymorphism modulates the gene's output level.

The Mechanism

The -971G>A substitution at rs4783961 lies within a potential AvaI restriction site in the CETP promoter. Studies of nearby promoter variants (including the well-characterized TaqIB rs708272 and the -629C>A substitution) have established that CETP promoter haplotypes collectively regulate CETP transcription in hepatocytes. The A allele at this position is thought to reduce CETP promoter activity, lowering CETP protein secretion from the liver. With less CETP circulating, the transfer of cholesteryl esters from HDL to VLDL/LDL slows, and HDL-C accumulates on the standard lipid panel.

The rs4783961 locus is in linkage disequilibrium¹¹ linkage disequilibrium
a statistical correlation between alleles at nearby positions, meaning they tend to be inherited together with other CETP promoter variants including rs3764261, rs1800775, and the widely-studied TaqIB (rs708272). Genetic tests may capture this regulatory haplotype through any of these markers; their effects on CETP expression are mechanistically convergent.

The Evidence

A Taiwanese cohort study of 3,023 participants²² Taiwanese cohort study of 3,023 participants
Huang et al. Cholesteryl Ester Transfer Protein Genetic Variants Associated with Risk for Type 2 Diabetes and Diabetic Kidney Disease in Taiwanese Population. Genes (Basel), 2019 found that the A allele at rs4783961 was independently associated with a 1.71 mg/dL increase in HDL-C per allele, a modest but statistically significant effect. The same study reported that A-allele carriers had a reduced risk of type 2 diabetes (OR 0.82, 95% CI 0.71–0.96), consistent with a role for CETP-mediated HDL elevation in improving insulin sensitivity.

A Mexican case-control study³³ Mexican case-control study
Vargas-Alarcón et al. The rs4783961 and rs708272 genetic variants of the CETP gene are associated with coronary artery disease, but not with restenosis after coronary stenting. Arch Cardiol Mex, 2022 of 826 subjects found the opposite directional signal for cardiovascular outcomes: the A allele was associated with increased coronary artery disease risk under the codominant model (OR 2.03) and dominant model (OR 1.83). This counterintuitive finding — where the HDL-raising allele associates with higher CAD risk — echoes lessons from CETP inhibitor trials (anacetrapib, dalcetrapib, torcetrapib), which repeatedly showed that pharmacologically raising HDL-C via CETP inhibition does not reliably reduce CAD events.

However, a 2023 meta-analysis⁴⁴ 2023 meta-analysis
Zhang et al. Association of the polymorphisms of the cholesteryl ester transfer protein gene with coronary artery disease: a meta-analysis. Front Cardiovasc Med, 2023 found no significant association between rs4783961 and CAD across multiple genetic models, in contrast to the positive signals seen for rs708272 and rs1800775 at the same locus. This discordance suggests that rs4783961 may be a less potent regulatory variant than TaqIB or that its effects are population-specific.

An Inuit population study⁵⁵ Inuit population study
Rudkowska et al. Omega-3 fatty acids, polymorphisms and lipid related cardiovascular disease risk factors in the Inuit population. Nutr Metab (Lond), 2013 showed that AG heterozygotes who consumed higher levels of n-3 PUFAs had stronger beneficial lipid effects — including lower triglycerides and better HDL-C — than GG or AA homozygotes at the same omega-3 intake level, suggesting a gene-diet interaction that amplifies the A allele's favorable lipid direction.

Practical Actions

For GG homozygotes (~25% of Europeans), CETP promoter activity is at reference level with standard CETP expression and typical HDL-C. No genotype-specific intervention is needed for this variant alone.

For AG heterozygotes (~50% of Europeans), one A allele moderately reduces CETP expression and modestly raises HDL-C. The n-3 PUFA interaction data suggest that maintaining adequate omega-3 intake amplifies the beneficial lipid effect seen in this genotype. Monitoring HDL-C alongside triglycerides and LDL-C gives the most informative cardiovascular picture.

For AA homozygotes (~25% of Europeans), two A alleles maximally suppress CETP promoter activity, producing the highest HDL-C in this genotype class. The conflicting CAD outcome data — HDL-C rising without clear proportional cardiovascular benefit — warrants a more comprehensive cardiovascular assessment beyond total HDL-C alone. Particle-level lipid testing (NMR lipoprofile or apoA-I measurement) can clarify whether the elevated HDL-C reflects genuinely protective reverse cholesterol transport capacity.

Interactions

rs4783961 is part of a CETP promoter haplotype block that includes rs3764261, rs1800775, and the TaqIB variant (rs708272). These variants are in moderate to high linkage disequilibrium and their effects on CETP expression and HDL-C levels are partially correlated. When multiple CETP SNPs are reported, rs708272 (TaqIB) is the most extensively studied and the better-powered single marker; rs4783961 adds incremental resolution of the same regulatory haplotype.

The AG genotype at rs4783961 shows amplified beneficial lipid responses in the presence of high n-3 PUFA intake (documented in the Inuit cohort), consistent with omega-3-mediated modulation of CETP expression and activity that has been described for other CETP variants. This interaction suggests that maximizing omega-3 intake is specifically valuable for A-allele carriers at this locus — not generic advice applicable to all genotypes.

For interactions with non-CETP lipid variants: CETP promoter variants interact additively with LIPC variants (rs1532085, rs1800588) to modulate HDL-C levels, but studies show the quality of HDL particle function — not just the quantity — determines cardiovascular benefit. The combination of a CETP promoter A allele and a LIPC promoter A allele may produce the highest nominal HDL-C while also carrying the most complex cardiovascular interpretation, as both raise HDL through particle accumulation mechanisms rather than increased reverse cholesterol transport throughput.